Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade®) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Potts, B.C., Albitar, M.X., Anderson, K.C., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., Cusack, J.C., Fenical, W., Ghobrial, I.M., Groll, M., Jensen, P.R., Lam, K.S., Lloyd, G.K., McBride, W., McConkey, D.J., Miller, C.P., Neuteboom, S.T.C., Oki, Y., Ovaa, H., Pajonk, F., Richardson, P.G., Roccaro, A.M., Sloss, C.M., Spear, M.A., Valashi, E., Younes, A., Palladino, M.A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3712795/
https://ncbi.nlm.nih.gov/pubmed/21247382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados